The Singulair lawsuit is one of the biggest pharmaceutical cases heading into 2026, with thousands of families alleging that Merck’s popular asthma drug caused severe neuropsychiatric injuries. If you or your child took montelukast and experienced depression, suicidal thoughts, or behavioral changes, you may be entitled to compensation.
This article breaks down everything happening with the litigation right now. You will learn about estimated settlement amounts, who qualifies, how to file, and critical deadlines you cannot afford to miss.
Here is a fact that shocks most people: the FDA knew about neuropsychiatric risks linked to Singulair for over a decade before adding its strongest safety warning in March 2020. That delay is at the heart of these lawsuits.
We are covering 2026 developments, payout projections, the MDL process, and eligibility rules in plain language. No legal jargon. No runaround.
What Is the Singulair Lawsuit About
The Singulair lawsuit is a collection of legal claims against Merck & Co. alleging the company failed to warn patients about serious psychiatric side effects caused by montelukast sodium. Plaintiffs say Merck knew about these risks for years and did not adequately disclose them.
Singulair was approved by the FDA in 1998. It became one of the most prescribed asthma and allergy medications in the United States, especially for children. At its peak, tens of millions of prescriptions were written each year.
The core legal argument centers on “failure to warn.” Plaintiffs claim Merck had data showing montelukast could cause depression, anxiety, aggression, hallucinations, and suicidal thoughts. Despite this data, the company allegedly minimized or buried these risks on its drug labels.
| Detail | Info |
|---|---|
| Defendant | Merck & Co., Inc. |
| Drug | Singulair (montelukast sodium) |
| Primary Allegation | Failure to warn about neuropsychiatric side effects |
| FDA Approval Year | 1998 |
| Black Box Warning Added | March 2020 |
| Federal Court | U.S. District Court, District of New Jersey |
Thousands of individual lawsuits have been filed. Many involve children who were prescribed Singulair for asthma or seasonal allergies and later developed severe behavioral or psychiatric problems.
The lawsuits do not claim the drug should never have existed. They claim Merck should have told doctors and patients about the real risks much sooner.
Singulair Lawsuit Update for 2026
As of 2026, the Singulair litigation continues to move through the federal multidistrict litigation process in New Jersey. The MDL has consolidated thousands of individual cases under one judge to streamline pretrial proceedings.
Bellwether trials are the next major milestone. These are test cases selected to go to trial first. Their outcomes will signal how juries view the evidence and will heavily influence any future settlement talks.
Throughout 2025, the court focused on expert witness challenges (Daubert motions) and discovery disputes. Merck has aggressively fought to exclude plaintiff expert testimony about the connection between montelukast and psychiatric injuries.
| 2026 Milestone | Expected Timeframe |
|---|---|
| Bellwether Case Selection | Early to Mid 2026 |
| Expert Witness Rulings | First Half of 2026 |
| Potential First Trial | Late 2026 |
| Settlement Discussions | Likely after first trial verdict |
If the court allows plaintiff experts to testify, that is a significant win for the thousands of families waiting for resolution. Expert rulings could come in the first half of 2026.
No global settlement has been reached yet. That is normal for mass torts at this stage. Settlements almost always happen after bellwether trials show both sides what a jury might decide.
Keep your eyes on late 2026. That is when the first trial could happen, and it will set the tone for everything that follows.
Singulair Settlement Amounts: What to Expect
No official Singulair settlement amounts have been announced yet because the litigation has not reached the settlement phase. However, legal analysts and attorneys involved in the cases have offered estimated ranges based on comparable pharmaceutical lawsuits.
Settlement projections depend heavily on the type and severity of injury. A child who attempted suicide after taking montelukast will have a vastly different case value than an adult who experienced moderate anxiety.
| Injury Severity | Estimated Settlement Range |
|---|---|
| Mild (anxiety, sleep disturbances, nightmares) | $10,000 to $50,000 |
| Moderate (depression, behavioral changes, OCD symptoms) | $50,000 to $200,000 |
| Severe (suicidal ideation, suicide attempts, hospitalization) | $200,000 to $500,000 or more |
| Wrongful Death (suicide attributed to montelukast) | $500,000 to $1,000,000 or more |
These are estimates only. They are based on historical outcomes in similar pharmaceutical failure-to-warn cases like Zoloft, Accutane, and Risperdal.
The actual amounts will depend on several factors:
- Strength of medical evidence linking the injury to montelukast
- Duration of drug use
- Age of the patient (pediatric cases often receive higher awards)
- Severity and permanence of the psychiatric injury
- Whether Merck’s conduct is found to be especially reckless
Think of it like a car accident claim. Two people in the same crash can get very different payouts based on their specific injuries and medical records.
Singulair Lawsuit Payout Per Person
The Singulair lawsuit payout per person will vary based on individual case strength and the tier system that a future settlement might use. There is no one-size-fits-all number.
In most mass tort settlements, a tiered payout structure is used. Cases are sorted into categories based on injury severity, medical documentation, and proof of causation. Higher tiers get larger payouts.
Here is what that might look like based on similar pharmaceutical settlements:
- Tier 1 (Highest): Wrongful death or permanent psychiatric disability. Potential payouts of $500,000 or more.
- Tier 2: Suicide attempts, psychiatric hospitalization, or severe self-harm. Potential payouts of $200,000 to $500,000.
- Tier 3: Diagnosed depression, severe anxiety, or significant behavioral changes requiring treatment. Potential payouts of $50,000 to $200,000.
- Tier 4 (Lowest): Nightmares, sleep disturbances, mild mood changes. Potential payouts of $10,000 to $50,000.
Attorney fees typically range from 33% to 40% of the settlement. That means if your case settles for $150,000, your take-home might be around $90,000 to $100,000 after legal fees and costs.
The best way to maximize your payout is to have strong medical records. Hospital visits, therapy records, psychiatric diagnoses, and prescription histories all strengthen a claim significantly.
Cases involving children tend to generate higher payouts. Juries and settlement administrators recognize that psychiatric harm to a child can affect their entire life trajectory.
Key Takeaway: No Singulair settlement has been finalized yet, but estimated payouts range from $10,000 for mild cases to over $1,000,000 for wrongful death claims, with bellwether trials in late 2026 likely driving settlement negotiations.
Is the Singulair Lawsuit a Class Action
The Singulair lawsuit is not a class action. It is a mass tort, which works differently in important ways that affect how much money individual plaintiffs can receive.
In a class action, one lawsuit represents everyone. All members of the class get the same outcome, usually a small payout split among thousands or millions of people. Think of those $5 checks you sometimes get in the mail from some product settlement.
Mass torts are different. Each person files their own individual lawsuit. Your case is evaluated on your specific injuries, your medical records, and your unique circumstances. This means payouts can be much larger.
| Feature | Class Action | Mass Tort |
|---|---|---|
| Case Type | One lawsuit for everyone | Individual lawsuits grouped together |
| Individual Evaluation | No | Yes |
| Payout Range | Usually small (under $500) | Can be $10,000 to $1,000,000+ |
| Medical Proof Required | Minimal | Extensive |
| Trial Possibility | Rare | Bellwether trials common |
The Singulair cases are consolidated in an MDL, which is a federal organizational tool. It keeps thousands of individual lawsuits moving efficiently without forcing every single one to trial separately.
This is actually better for plaintiffs. Your case is treated as unique, and your settlement reflects your actual harm, not some averaged-out number shared with a million strangers.
Montelukast Lawsuit: The Drug Behind the Claims
Montelukast is the generic name for Singulair, and it is the active ingredient at the center of every claim in this litigation. Understanding what this drug does helps explain why the lawsuits exist.
Montelukast is a leukotriene receptor antagonist. In plain English, it blocks certain chemicals in your body that cause inflammation, airway constriction, and allergic reactions. Doctors prescribe it for asthma, exercise-induced bronchoconstriction, and seasonal allergies.
The drug works in the brain too. Leukotriene receptors exist in the central nervous system. When montelukast crosses the blood-brain barrier and interacts with these receptors, it can alter neurological function. That is the mechanism scientists believe causes the psychiatric side effects.
Here is what makes the montelukast lawsuit particularly strong:
- Merck’s own clinical trial data showed neuropsychiatric adverse events before FDA approval
- Post-marketing reports to the FDA’s MedWatch system numbered in the thousands
- The FDA required label changes in 2009 but did not add the black box warning until 2020
- Generic versions of montelukast now carry the same warning
The lawsuit is not just against the brand name Singulair. Plaintiffs who took generic montelukast may have claims depending on their state’s laws regarding generic drug manufacturer liability.
Roughly 30 million prescriptions for montelukast are still written each year in the United States. The drug remains on the market, but with significantly stronger warnings than it carried for most of its commercial life.
Singulair Side Effects at the Center of the Lawsuit
The Singulair side effects driving these lawsuits are primarily neuropsychiatric in nature. These are not the typical headache-and-nausea side effects listed on most drug labels. They are severe mental health and behavioral changes.
The FDA identified the following side effects as warranting the strongest possible warning:
- Agitation and aggression, including hostility
- Depression
- Anxiety
- Suicidal thoughts and behavior
- Hallucinations
- Disorientation and confusion
- Sleep disturbances, including insomnia and vivid nightmares
- Obsessive-compulsive symptoms
- Memory impairment
- Attention disturbances
- Tremor and seizures (less common)
- Speech problems, including stuttering and stammering
Many of these side effects appeared in children as young as two years old. Parents reported sudden personality changes, night terrors, violent outbursts, and emotional breakdowns that started after beginning montelukast.
| Side Effect Category | Examples |
|---|---|
| Mood-Related | Depression, anxiety, irritability |
| Behavioral | Aggression, agitation, hostility |
| Sleep-Related | Nightmares, insomnia, sleepwalking |
| Cognitive | Memory problems, confusion, attention issues |
| Severe Psychiatric | Suicidal thoughts, hallucinations, self-harm |
What makes these side effects so legally significant is that many of them persisted even after patients stopped taking the drug. Some families report that their children have never fully returned to their pre-Singulair baseline.
Key Takeaway: The Singulair lawsuit focuses on severe neuropsychiatric side effects including suicidal thoughts, depression, aggression, and hallucinations, many of which appeared in young children and persisted after stopping the drug.
Singulair Neuropsychiatric Side Effects Explained
Singulair neuropsychiatric side effects refer to the mental health and behavioral changes caused by montelukast’s interaction with the central nervous system. These effects go beyond typical drug reactions and can fundamentally alter a person’s personality and mental state.
The term “neuropsychiatric” covers any symptom that involves both neurological function (brain and nerve activity) and psychiatric health (mood, behavior, thought patterns). Montelukast affects both because leukotriene receptors are present throughout the brain.
Research published in peer-reviewed journals has documented the connection. A 2019 study in the journal Pharmacotherapy found a statistically significant association between montelukast use and neuropsychiatric adverse events, particularly in pediatric patients.
The effects can appear quickly. Some patients and families report changes within the first few days of starting the medication. Others describe a gradual onset over weeks or months, making it harder to connect the dots.
Quick Facts: Singulair Neuropsychiatric Effects
- Can appear in patients of any age, but most reported in children ages 2 to 17
- Onset can be as fast as 24 to 48 hours after first dose
- Some effects resolve after stopping the drug; others persist for months or years
- The FDA received over 100 reports of completed suicides potentially linked to montelukast
- Neuropsychiatric symptoms are now included in the drug’s black box warning
The persistence of symptoms is one of the most troubling aspects. A child who develops severe anxiety or OCD symptoms on Singulair may continue to struggle with those conditions long after the prescription ends.
The Singulair Black Box Warning and What It Means
The Singulair black box warning is the FDA’s most serious safety alert, and it was added to montelukast’s label in March 2020. A black box warning means the FDA has determined there are serious or life-threatening risks associated with the drug.
This is the strongest warning the FDA can place on a medication short of pulling it from the market entirely. Only a small percentage of drugs carry black box warnings. When you see one, it means the risk is real, documented, and potentially fatal.
The March 2020 warning specifically states that montelukast can cause:
- Serious mental health side effects
- Suicidal thoughts and actions
- Agitation, aggression, and hostility
- Depression and anxiety
- Sleep problems including nightmares
- Hallucinations
The warning also restricts montelukast’s recommended use. The FDA now advises that Singulair should only be prescribed for allergic rhinitis if the patient has not responded to other treatments. It should no longer be a first-line allergy medication.
| Timeline | FDA Action |
|---|---|
| 1998 | Singulair approved with standard label |
| 2008 | FDA begins reviewing neuropsychiatric reports |
| 2009 | Precautions section updated (not a black box) |
| 2020 | Black box warning added |
| 2020 to present | Restricted use recommendation in effect |
The lawsuit’s core argument is timing. Merck and the FDA had data about these risks for over a decade before the black box warning appeared. Plaintiffs argue that earlier, stronger warnings would have prevented thousands of injuries.
Singulair and Suicidal Thoughts: The Most Serious Allegation
Singulair and suicidal thoughts represent the most serious and emotionally devastating claims in the entire litigation. Families allege that montelukast caused their loved ones to develop suicidal ideation, attempt suicide, or die by suicide.
The FDA’s adverse event reporting system has logged over 100 completed suicides in patients taking montelukast. Thousands more reports describe suicidal thoughts, self-harm, and suicide attempts.
Many of these reports involve children and teenagers. A parent who gives their child an asthma pill does not expect that pill to make their child want to die. That disconnect between expectation and reality is what fuels the strongest claims in this litigation.
The legal argument is straightforward. Merck knew montelukast could cause suicidal ideation. Internal documents and clinical data reportedly showed this risk. Yet the drug label for years described these events as rare and buried them in fine print.
Quick Facts: Suicidal Thoughts and Montelukast
- Over 100 completed suicides reported to FDA MedWatch
- Thousands of additional reports of suicidal thoughts and self-harm
- Children as young as 5 have been reported to express suicidal ideation while on the drug
- The black box warning now explicitly mentions suicidal thoughts and actions
- Wrongful death cases carry the highest potential settlement values
Cases involving suicide or suicide attempts typically fall into the highest settlement tier. They involve the most severe harm, the clearest evidence of failure to warn, and the strongest emotional impact on a jury.
If you lost a family member to suicide while they were taking Singulair, your case may be among the strongest in the entire MDL.
Key Takeaway: Suicidal thoughts and completed suicides linked to Singulair are the most serious allegations in the lawsuit, with over 100 deaths reported to the FDA and wrongful death cases projected to receive the highest settlement payouts.
Singulair Lawsuit for Children and Pediatric Cases
The Singulair lawsuit for children represents the largest segment of claims in the litigation. Montelukast was heavily marketed as a safe, daily asthma and allergy medication for kids as young as six months old.
At its peak, Singulair was one of the most prescribed pediatric medications in America. Merck promoted it as a convenient chewable tablet, easy for kids to take. Millions of parents trusted their doctors and gave their children this drug every single day.
The pediatric cases are particularly powerful because:
- Children cannot consent to medication; parents relied entirely on safety information provided by Merck and their doctors
- Developing brains may be more vulnerable to montelukast’s neurological effects
- Behavioral changes in young children were often misdiagnosed as ADHD, autism spectrum disorder, or oppositional defiant disorder
- Some children were prescribed additional psychiatric medications to treat side effects actually caused by Singulair
Many families describe a pattern. Their child started Singulair. Within weeks, the child became aggressive, anxious, or emotionally unstable. The child was then evaluated for behavioral disorders and sometimes put on additional medications. Only later did the family learn about Singulair’s neuropsychiatric risks.
| Pediatric Case Factor | Detail |
|---|---|
| Age Range in Claims | 6 months to 17 years |
| Most Common Reported Effects | Nightmares, aggression, anxiety, mood swings |
| Misdiagnosis Risk | High (often labeled as ADHD or behavioral disorder) |
| Duration of Effects | Some children report symptoms years after stopping |
| Legal Standing | Parents or guardians file on behalf of minor children |
If your child was prescribed Singulair and developed behavioral or psychiatric symptoms, the statute of limitations clock may have started later than you think. Many states toll the statute for minors, giving families extra time to file.
Singulair Lawsuit Eligibility Requirements
Singulair lawsuit eligibility depends on a few key factors that determine whether you have a viable legal claim. Not everyone who took the drug qualifies, but the criteria are broader than many people realize.
To be eligible, you generally need to meet these requirements:
- You or your child took Singulair (montelukast) in any form: brand name or generic
- You experienced neuropsychiatric side effects during or after taking the drug
- You have medical records documenting the side effects or psychiatric symptoms
- You can establish a timeline showing the symptoms began during or shortly after montelukast use
- You have not missed the statute of limitations in your state
Medical documentation is the single most important factor. Pharmacy records proving you filled a montelukast prescription, combined with medical records showing psychiatric symptoms, form the backbone of your case.
| Eligibility Factor | What You Need |
|---|---|
| Drug Use | Proof of Singulair or generic montelukast prescription |
| Side Effects | Documented neuropsychiatric symptoms |
| Medical Records | Therapy, hospital, or doctor records showing psychiatric treatment |
| Timeline | Symptoms started during or after drug use |
| Statute of Limitations | Claim filed within your state’s deadline |
You do not need to have taken the brand-name Singulair specifically. Generic montelukast contains the same active ingredient and carries the same black box warning.
You do not need to have been hospitalized. Documented outpatient therapy, psychiatric prescriptions, and even school behavioral records can support a claim.
Who Qualifies for the Singulair Lawsuit
Who qualifies for the Singulair lawsuit includes adults, children (through their parents), and the families of anyone who died by suicide while taking montelukast. The pool of potential plaintiffs is large because the drug was so widely prescribed.
Here are the groups most likely to have strong claims:
- Children prescribed Singulair for asthma or allergies who developed behavioral problems, nightmares, aggression, depression, or suicidal thoughts
- Adults who took montelukast and developed new-onset depression, anxiety, suicidal ideation, or other psychiatric conditions
- Families of individuals who died by suicide while taking or shortly after stopping montelukast
- Patients who were misdiagnosed with psychiatric conditions (like ADHD or bipolar disorder) that were actually caused by montelukast
- Patients who were prescribed additional psychiatric medications to treat symptoms caused by Singulair
You do not need to still be taking the drug to qualify. Many plaintiffs stopped taking montelukast years ago but continue to experience lasting psychiatric effects.
People who took the drug and experienced no side effects do not have a claim. The lawsuit requires proof of actual harm.
Quick Facts: Who Qualifies
- Both brand-name Singulair and generic montelukast users qualify
- No minimum duration of drug use required
- Pediatric cases are among the strongest claims
- Wrongful death claims can be filed by surviving family members
- You can qualify even if you stopped the drug years ago
Key Takeaway: You may qualify for the Singulair lawsuit if you or your child took montelukast and developed neuropsychiatric symptoms, regardless of whether you used the brand name or generic version and regardless of when you stopped taking the drug.
How to File a Singulair Lawsuit
Filing a Singulair lawsuit starts with contacting a law firm that handles pharmaceutical mass tort cases. Most firms offer free case evaluations and work on contingency, meaning you pay nothing upfront.
Here is the general process from start to finish:
Step 1: Free Case Evaluation
You provide basic information about your drug use and side effects. An attorney reviews your situation and determines if you have a viable claim.
Step 2: Gather Medical Records
Your attorney will help collect pharmacy records, medical charts, psychiatric evaluations, therapy notes, and any other documentation linking your symptoms to montelukast.
Step 3: File Your Complaint
Your attorney drafts and files a formal legal complaint. If your case is in federal court, it will likely be transferred to the Singulair MDL in New Jersey.
Step 4: Discovery and Litigation
Your case enters the pretrial process. This includes document exchanges, depositions, and expert evaluations. You may need to answer questions about your medical history.
Step 5: Resolution
Your case either settles or goes to trial. In most mass torts, the vast majority of cases settle after bellwether trial results are known.
| Filing Step | What Happens |
|---|---|
| Case Evaluation | Attorney reviews your claim for free |
| Records Collection | Medical, pharmacy, and school records gathered |
| Complaint Filed | Lawsuit formally submitted to court |
| Discovery | Evidence exchanged between plaintiff and Merck |
| Settlement or Trial | Case resolved through negotiation or jury verdict |
You will not need to go to court in most cases. Mass tort settlements are typically handled through paperwork and attorney negotiations.
The most important thing you can do right now is preserve your records. Do not throw away prescription bottles, pharmacy printouts, or medical documents.
Singulair MDL: How the Federal Cases Are Organized
The Singulair MDL is formally known as In Re: Singulair (Montelukast Sodium) Products Liability Litigation, MDL No. 3028. It is centralized in the U.S. District Court for the District of New Jersey.
MDL stands for multidistrict litigation. It is a federal procedure that consolidates individual lawsuits involving common facts into one court for pretrial proceedings. This prevents conflicting rulings and speeds up the process.
Here is how it works. If you file a Singulair lawsuit in federal court in Texas, California, or any other state, your case can be transferred to New Jersey for the pretrial phase. If your case does not settle through the MDL process, it goes back to your original court for trial.
The MDL judge oversees:
- Discovery: Merck must turn over internal documents, emails, clinical data, and safety reports
- Expert witness challenges: Both sides argue about which scientific experts can testify
- Bellwether trials: A small number of representative cases are selected for trial to test the evidence
- Settlement negotiations: The judge often facilitates or encourages global settlement discussions
| MDL Detail | Info |
|---|---|
| MDL Number | 3028 |
| Court | U.S. District Court, District of New Jersey |
| Judge | Assigned federal judge overseeing all pretrial matters |
| Number of Cases | Thousands of individual claims consolidated |
| Current Phase | Pretrial discovery and expert challenges (as of early 2026) |
The bellwether trial process is critical. Think of it as a test run. A few cases go to trial, and the results tell everyone, including Merck, what a full-scale trial would look like. If Merck loses bellwether trials, they have strong incentive to settle the remaining cases.
Singulair Lawsuit Deadline: Statute of Limitations
The Singulair lawsuit deadline depends on your state’s statute of limitations for product liability or personal injury claims. There is no single national deadline, and missing your state’s cutoff means losing your right to sue permanently.
Most states set the statute of limitations at two to three years. However, the clock does not always start on the date you took the drug. In many pharmaceutical cases, the “discovery rule” applies.
The discovery rule says the clock starts when you knew, or reasonably should have known, that your injury was caused by the drug. For Singulair cases, many attorneys argue the clock started in March 2020 when the FDA added the black box warning, because that is when the general public first learned about the severity of the risks.
| State Example | Statute of Limitations | Discovery Rule |
|---|---|---|
| California | 2 years | Yes, from date of discovery |
| Texas | 2 years | Yes, from date of discovery |
| New York | 3 years | Yes, in most cases |
| Florida | 4 years (recently changed) | Yes, from date of discovery |
| Pennsylvania | 2 years | Yes, from date of discovery |
Special rules for children: Most states toll (pause) the statute of limitations for minors. The clock may not start until the child turns 18. This gives families significantly more time to file.
Do not assume you have missed the deadline. Even if years have passed since your child took Singulair, the discovery rule and tolling provisions might keep your claim alive.
The safest move is to get a free case evaluation now. An attorney can quickly determine whether your state’s deadline has passed.
Key Takeaway: There is no single national deadline for the Singulair lawsuit; each state has its own statute of limitations, but the discovery rule and special provisions for children may give you more time than you think to file your claim.
Montelukast Settlement Update: Where Things Stand Now
The montelukast settlement update for 2026 is that no global settlement has been reached yet. The litigation remains in the pretrial phase, with both sides preparing for bellwether trials that could happen later this year.
This is not unusual for large pharmaceutical mass torts. Cases like Zantac, Roundup, and 3M earplugs all spent years in pretrial proceedings before settlements materialized. The Singulair litigation is following a similar trajectory.
Here is what has happened recently:
- Discovery continues: Merck has been producing internal documents and clinical trial data under court order
- Expert challenges: Both sides have filed Daubert motions challenging the other’s expert witnesses
- Case management orders: The court has set deadlines for key pretrial milestones throughout 2026
- Bellwether selection: The process of choosing representative cases for trial is underway or imminent
| Settlement Factor | Current Status |
|---|---|
| Global Settlement | Not yet reached |
| Bellwether Trials | Being selected, expected late 2026 |
| Expert Rulings | Pending in early to mid 2026 |
| Settlement Talks | Expected to intensify after first trial |
| Estimated Timeline to Resolution | Late 2026 to 2028 |
The expert witness rulings are the next critical event. If the judge allows plaintiff experts to testify about the link between montelukast and neuropsychiatric harm, Merck’s settlement incentive increases dramatically.
If plaintiff experts are excluded, it would be a major blow to the litigation. However, the weight of scientific evidence, the FDA’s own black box warning, and thousands of adverse event reports make exclusion unlikely.
Settlement talks typically accelerate after the first bellwether trial verdict. Whether Merck wins or loses that first trial will shape the entire settlement landscape for thousands of remaining cases.
Patience is necessary, but the litigation is moving forward. Every pretrial milestone completed brings this case closer to a resolution.
Frequently Asked Questions
How much money can I get from a Singulair lawsuit?
Most estimates place Singulair settlement payouts between $10,000 and $500,000 depending on injury severity.
Wrongful death cases involving suicide could exceed $1,000,000.
No official settlement has been announced yet, so these are projections based on similar pharmaceutical lawsuits.
Is there a deadline to file a Singulair lawsuit in 2026?
Yes, every state has its own statute of limitations, typically two to three years from when you discovered the connection between Singulair and your injury.
The discovery rule may extend your deadline, especially if you only recently learned about the risks.
Contact an attorney for a free evaluation to confirm your state’s specific deadline.
Can I file a Singulair lawsuit for my child?
Yes, parents and legal guardians can file a Singulair lawsuit on behalf of their minor child.
Most states also pause the statute of limitations for minors, giving families extra time to file.
Pediatric cases are among the strongest claims in the litigation because children cannot consent to medication risks.
What side effects qualify for a Singulair lawsuit?
Qualifying side effects include depression, anxiety, suicidal thoughts, aggression, hallucinations, nightmares, behavioral changes, and obsessive-compulsive symptoms.
Any neuropsychiatric symptom that appeared during or after montelukast use may qualify.
Medical documentation of these symptoms significantly strengthens your claim.
Has there been a Singulair settlement yet?
No global Singulair settlement has been reached as of 2026.
The litigation is in the pretrial phase, with bellwether trials expected later this year.
Settlement negotiations are expected to begin in earnest after the first trial verdict.
The Singulair lawsuit is real, it is active, and it is moving toward resolution. If you or your child took montelukast and suffered neuropsychiatric side effects, 2026 is a critical year to act.
Check whether you meet the eligibility requirements. Gather your medical and pharmacy records. Get a free case evaluation before your state’s deadline passes.
Do not wait for a settlement to be announced before getting started. The families who file early and organize their documentation now will be in the strongest position when payouts begin.
